Viracta Therapeutics shares were trading lower after it said it will end an ongoing trial of Nana-val and its board has initiated a process to explore strategic options. The strategic options being ...
Shares of Assembly Biosciences advanced after the company reported encouraging results from a clinical trial of its treatment for the hepatitis B virus. The stock was up 5.2% at $15.49 in premarket ...